Interactive Program Guide
Put your cursor over the icon or photo for a capsule summary or to learn more about our speakers

 8.30-9.00
UNAIDS has revised the numbers of people living with HIV/AIDS in India and Cambodia. New HIV infections are on the rise in Australia. What is happening in Thailand and our neighbouring countries?

 Epidemiology of HIV in the Asia/Pacific region [ Download ]

 Frits Van Griensven
 Associate Director for Research of the HIV/AIDS Program of the Thailand
 Ministry of Public Health - U.S. Centers for Disease Control and Prevention
 Collaboration  

9.00-9.30
We take a fresh look at Immune reconstitution Inflammatory Syndrome. How to manage this common complication of ARV therapy especially on patients with advance HIV disease?

 IRIS revisited [ Download ]

 Martyn French
 Professor of Clinical Immunology at the University of Western Australia and
 Professor of medicine at Royal Perth Hospital

9.30-10.00
As people take ART for many years, more move to second line therapy and new drugs become available, the pattern of ART-related morbidity is changing.

 Fats, sugar, cardiovascular and renal disease
 Changing causes of death and morbidity in the patients on HAART
[ Download ]

 Andrew Carr
 Associate Professor of Medicine, University of New South Wales, Sydney,
 Australia; Senior Staff Specialist, HIV, Immunology, and Infectious Diseases Unit,
 St. Vincent's Hospital, Sydney, Australia
BREAK

10.30 -11.00
With 28 ARV drugs from 6 classes to chose from, knowledge of drug interactions among ARVs and between ARVs and other drugs is key to successful patient care.The presentation will review known important and newly recognised drug interactions

 Drug-Drug Interactions in the practical treatment of HIV [ Download ]

 David Burger
 Associate Professor of Clinical Pharmacology, Radboud University, Nijmegen,
 The Netherlands

11.00-11.30
Resistance testing to current drugs is out of reach for most physicians. New drugs such as integrase and entry inhibitors also have resistance issues. How will the future of resistance testing impact on HIV care in low and middle income countries?

 The Future of Resistance Testing include testing for sensitivity to CCR5
 inhibitors and integrase inhibitors [ Download ]

 Daniel R. Kuritzkes
 Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts;
 Director of AIDS Research, Brigham and Women's Hospital, Boston, Massachusetts

 11.30-12.00
While new drugs effectively contol HIV, prevention is still the best medicine. This presentation will review research efforts to prevent HIV infection using barriers, vaccines and drugs

 HIV Prevention pipeline (Tenofovir, microbicides, vaccines) [ Download ]

 Joep Lange
 Professor of Medicine at the Academic Medical Center/University of Amsterdam.
 He is Chief Scientific Advisor of the International Antiviral Therapy Evaluation
 Center, Chairman of PharmAccess Foundation and a co-director of HIV-NAT
 
     
 
 
 
Copyrights 2007 HIV-NAT. All rights reserved